Enfermedad de Raynaud

Volver al artículo.

Referencias para el artículo

  1. Digiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am J Med 1989;86:158–64.
  2. Aylward M. Hexopal in Raynaud’s disease. J Int Med Res 1979;7:484–91.
  3. Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud’s phenomenon. J Int Med Res 1979;7:473–83.
  4. Ring EF, Bacon PA. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud’s phenomenon. J Int Med Res 1977;5:217–22.
  5. Belch JJF, Shaw B, O’Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud’s phenomenon: A double-blind study. Throm Haemost 1985;54(2):490–4.
  6. Gasser P, Martina B, Dubler B. Reaction of capillary blood cell velocity in nailfold capillaries to L-carnitine in patients with vasospastic disease. Drugs Exptl Clin Res 1997;23:39–43.
  7. Leppert J, Aberg H, Levin K, et al. The concentration of magnesium in erythrocytes in female patients with primary Raynaud’s phenomenon; fluctuation with the time of year. Angiology 1994;45:283–8.
  8. Smith WO, Hammarsten JF, Eliel LP. The clinical expression of magnesium deficiency. JAMA 1960;174:77–8.
  9. Turlapaty P, Altura BM. Magnesium deficiency produces spasms of coronary arteries; relationship to etiology of sudden death ischemic heart disease. Science 1980;208:198–200.
  10. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9 [review].
  11. Clement JL, Livecchi G, Jimenez C, et al. Modifications vasomotrices des extrémités lors l’exposition à des conditions thermiques défavorables. Méthodologie et résultant de l’étude de l’extrait de Ginkgo biloba. Acutal Angiol 1982;7:3–8.